Modern management of hyperlipidemia.
D053299:Apolipoprotein B-100; D001055:Apolipoproteins B / Q000378:metabolism; D001057:Apolipoproteins E / Q000378:metabolism; D002914:Chylomicrons / Q000378:metabolism; D003327:Coronary Disease / Q000209:etiology; D006801:Humans; D006937:Hypercholesterolemia / Q000628:therapy; D006949:Hyperlipidemias / Q000378:metabolism / Q000628:therapy*; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008071:Lipoprotein Lipase / Q000378:metabolism; D008074:Lipoproteins / Q000378:metabolism*; D008079:Lipoproteins, VLDL / Q000378:metabolism; D008099:Liver / Q000503:physiopathology; D011956:Receptors, Cell Surface / Q000502:physiology; D018110:Receptors, Lipoprotein; D014280:Triglycerides / Q000378:metabolism
D053299:Apolipoprotein B-100; D001055:Apolipoproteins B; D001057:Apolipoproteins E; D002914:Chylomicrons; D000960:Hypolipidemic Agents; D008074:Lipoproteins; D008079:Lipoproteins, VLDL; D011956:Receptors, Cell Surface; D018110:Receptors, Lipoprotein; D014280:Triglycerides; C032531:apolipoprotein B,E receptor; D008071:Lipoprotein Lipase